You are here

  • Home
  • Archive
  • Volume 81, Issue 5
  • Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Article metrics

Article menu
Download PDFPDF
Epidemiology
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

AbstractFullPdf
Jan 202220062056589
Feb 202210631045301
Mar 2022517496175
Apr 2022910908290
May 2022569577322
Jun 2022357347122
Jul 2022316299106
Aug 202224722378
Sep 202223522782
Oct 202219318986
Nov 202219717971
Dec 202216315273
Jan 202316015054
Feb 202314413951
Mar 202319417282
Apr 20233722220
May 202347366
Jun 2023294218
Jul 20233701412
Aug 20232731214
Sep 20234751716
Oct 20233112523
Nov 20231681410
Dec 202326693
Jan 2024184188
Feb 202413980
Mar 20242582615
Total1085473512617